MX2018004556A - Metodo de mejora ex vivo de actividad de celula inmune para inmunoterapia del cancer con un compuesto ablativo de molecula pequeña. - Google Patents

Metodo de mejora ex vivo de actividad de celula inmune para inmunoterapia del cancer con un compuesto ablativo de molecula pequeña.

Info

Publication number
MX2018004556A
MX2018004556A MX2018004556A MX2018004556A MX2018004556A MX 2018004556 A MX2018004556 A MX 2018004556A MX 2018004556 A MX2018004556 A MX 2018004556A MX 2018004556 A MX2018004556 A MX 2018004556A MX 2018004556 A MX2018004556 A MX 2018004556A
Authority
MX
Mexico
Prior art keywords
host
tumor
cancer immunotherapy
small molecule
immune cell
Prior art date
Application number
MX2018004556A
Other languages
English (en)
Inventor
A Wachter Eric
Singer Jamie
Sarnaik Amod
Philon-Thomas Shari
Liu Hao
Original Assignee
Provectus Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provectus Pharmatech Inc filed Critical Provectus Pharmatech Inc
Publication of MX2018004556A publication Critical patent/MX2018004556A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método de inmunoterapia del cáncer en el cual ``agentes anticancerígenos inmunes inducidos´´ son aislados después de ser inducidos en un anfitrión animal por administración intralesión (IL) de un compuesto ablativo de tumor de xanteno halogenado en un tumor canceroso sólido de ese animal anfitrión. Una muestra de los agentes anticancerígenos inmunes inducidos es removida (recolectada) del anfitrión que tiene el tumor, depositada en un banco si se desea, cultivada y preferiblemente expandida para formar una composición de agente anticancerígeno inmune específico del tumor enriquecido de manera inmunológicamente efectiva. Esa composición es reintroducida al anfitrión del cual fueron tomados los agentes anticancerígenos inmunes inducidos predecesores, o en otro anfitrión inmunológicamente adecuado que lo necesite.
MX2018004556A 2015-12-18 2016-12-08 Metodo de mejora ex vivo de actividad de celula inmune para inmunoterapia del cancer con un compuesto ablativo de molecula pequeña. MX2018004556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/974,357 US10130658B2 (en) 2015-12-18 2015-12-18 Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
PCT/US2016/065542 WO2017105993A1 (en) 2015-12-18 2016-12-08 Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound

Publications (1)

Publication Number Publication Date
MX2018004556A true MX2018004556A (es) 2019-04-22

Family

ID=57868325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004556A MX2018004556A (es) 2015-12-18 2016-12-08 Metodo de mejora ex vivo de actividad de celula inmune para inmunoterapia del cancer con un compuesto ablativo de molecula pequeña.

Country Status (9)

Country Link
US (2) US10130658B2 (es)
EP (1) EP3347041A1 (es)
JP (1) JP6773788B2 (es)
KR (1) KR20180094903A (es)
CN (1) CN108495648A (es)
CA (1) CA3006302C (es)
HK (1) HK1257690A1 (es)
MX (1) MX2018004556A (es)
WO (1) WO2017105993A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200144562A (ko) * 2018-05-16 2020-12-29 프로벡투스 파마테크 인코포레이티드 난치성 소아 고형 종양에 대한 할로겐화-크산텐의 시험관 내 및 이종이식 항-종양
US11419844B2 (en) 2019-11-19 2022-08-23 Provectus Pharmatech, Inc. Halogenated xanthene composition and method for treating hematologic cancers
WO2021195400A1 (en) 2020-03-26 2021-09-30 Provectus Pharmatech, Inc. Novel uses of halogenated xanthenes in oncology and virology
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
CN112530581B (zh) * 2020-12-03 2023-11-21 安徽医科大学第一附属医院 一种前列腺癌患者的免疫分子分类系统及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927749A (en) 1986-04-09 1990-05-22 Jeanette Simpson Reagent for cell separation
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
EP1540627A4 (en) 2002-09-20 2006-08-16 Dendreon Corp IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING MODERATELY DIFFERENTIATED CANCERS
CA2682661C (en) 2007-03-22 2017-03-14 Dendreon Corporation Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
WO2009114547A2 (en) 2008-03-10 2009-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced dendritic cells for cancer immunotherapy
CN102281917A (zh) * 2008-11-24 2011-12-14 格雷迪安特研究有限责任公司 软组织的光热治疗
US20110123483A1 (en) 2009-11-23 2011-05-26 Deutsches Krebsforschungszentrum Hmgb1 for cancer treatment
CN103097888B (zh) * 2010-05-06 2016-03-09 赛昆塔有限责任公司 利用克隆型谱监测健康和疾病状态
US9149515B2 (en) * 2010-06-02 2015-10-06 Bavarian Nordic A/S Interferon-alpha-producing bone marrow dendritic cells
JP6322413B2 (ja) 2011-03-10 2018-05-09 プロヴェクタス ファーマテック，インク． 改善されたがん治療のための局所および全身性免疫修飾療法の組み合わせ
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists

Also Published As

Publication number Publication date
KR20180094903A (ko) 2018-08-24
CA3006302A1 (en) 2017-06-22
US20190030074A1 (en) 2019-01-31
WO2017105993A1 (en) 2017-06-22
HK1257690A1 (zh) 2019-10-25
US10130658B2 (en) 2018-11-20
EP3347041A1 (en) 2018-07-18
JP2018537478A (ja) 2018-12-20
CA3006302C (en) 2021-08-31
US20170173079A1 (en) 2017-06-22
CN108495648A (zh) 2018-09-04
JP6773788B2 (ja) 2020-10-21

Similar Documents

Publication Publication Date Title
MX2018004556A (es) Metodo de mejora ex vivo de actividad de celula inmune para inmunoterapia del cancer con un compuesto ablativo de molecula pequeña.
NZ730563A (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
GB2573406A (en) Tumor infiltrating lymphocytes and methods of therapy
MX2023013462A (es) Muteinas de interleucina 21 y usos de las mismas.
MX2019005617A (es) Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
WO2018089669A3 (en) Immunotherapeutic tumor treatment method
BR112017010110A2 (pt) anticorpos contra cd73 e usos do mesmo
MX2019002564A (es) Composiciones de agente de unión de albúmina-paclitaxel y métodos de uso y elaboración de las mismas.
GB2557123A (en) Modified cells and methods of therapy
MX2020005634A (es) Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
NZ619576A (en) Compositions and methods for the treatment of infections and tumors
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
BR212016030926U2 (pt) conjugados de alvo e partículas e formulações dos mesmos
EA202091219A1 (ru) Культивирование плаценты с целью выделения экзосом
WO2016172494A3 (en) Combination of immunotherapy with local chemotherapy for the treatment of malignancies
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
BR112017019189A8 (pt) Agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
CN106459011A8 (zh) 作为抗肿瘤化合物的σ‑2受体配体药物缀合物、其合成方法及其用途
IL268744A (en) Methods for increasing the immunogenicity of tumors and preparations for autologous immunotherapeutic products against cancer using tumor cells and adapted dendritic cells
EP4252852A3 (en) Methods and materials for treating cancer
WO2018050656A3 (en) Inhibitors of heat shock factors and uses thereof
WO2014005153A3 (en) Methods for treating mds1-evi1 mediated cancer